IBDEI2DA ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,40139,2)
 ;;=^5001803
 ;;^UTILITY(U,$J,358.3,40140,0)
 ;;=C92.52^^156^1952^7
 ;;^UTILITY(U,$J,358.3,40140,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40140,1,3,0)
 ;;=3^Acute myelomonocytic leukemia, in relapse
 ;;^UTILITY(U,$J,358.3,40140,1,4,0)
 ;;=4^C92.52
 ;;^UTILITY(U,$J,358.3,40140,2)
 ;;=^5001806
 ;;^UTILITY(U,$J,358.3,40141,0)
 ;;=C92.11^^156^1952^18
 ;;^UTILITY(U,$J,358.3,40141,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40141,1,3,0)
 ;;=3^Chronic myeloid leukemia, BCR/ABL-positive, in remission
 ;;^UTILITY(U,$J,358.3,40141,1,4,0)
 ;;=4^C92.11
 ;;^UTILITY(U,$J,358.3,40141,2)
 ;;=^5001793
 ;;^UTILITY(U,$J,358.3,40142,0)
 ;;=C92.12^^156^1952^19
 ;;^UTILITY(U,$J,358.3,40142,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40142,1,3,0)
 ;;=3^Chronic myeloid leukemia, BCR/ABL-positive, in relapse
 ;;^UTILITY(U,$J,358.3,40142,1,4,0)
 ;;=4^C92.12
 ;;^UTILITY(U,$J,358.3,40142,2)
 ;;=^5001794
 ;;^UTILITY(U,$J,358.3,40143,0)
 ;;=C92.21^^156^1952^13
 ;;^UTILITY(U,$J,358.3,40143,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40143,1,3,0)
 ;;=3^Atypical chronic myeloid leukemia, BCR/ABL-neg, in remission
 ;;^UTILITY(U,$J,358.3,40143,1,4,0)
 ;;=4^C92.21
 ;;^UTILITY(U,$J,358.3,40143,2)
 ;;=^5001796
 ;;^UTILITY(U,$J,358.3,40144,0)
 ;;=C92.22^^156^1952^14
 ;;^UTILITY(U,$J,358.3,40144,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40144,1,3,0)
 ;;=3^Atypical chronic myeloid leukemia, BCR/ABL-neg, in relapse
 ;;^UTILITY(U,$J,358.3,40144,1,4,0)
 ;;=4^C92.22
 ;;^UTILITY(U,$J,358.3,40144,2)
 ;;=^5001797
 ;;^UTILITY(U,$J,358.3,40145,0)
 ;;=C93.01^^156^1952^3
 ;;^UTILITY(U,$J,358.3,40145,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40145,1,3,0)
 ;;=3^Acute monoblastic/monocytic leukemia, in remission
 ;;^UTILITY(U,$J,358.3,40145,1,4,0)
 ;;=4^C93.01
 ;;^UTILITY(U,$J,358.3,40145,2)
 ;;=^5001820
 ;;^UTILITY(U,$J,358.3,40146,0)
 ;;=C93.02^^156^1952^4
 ;;^UTILITY(U,$J,358.3,40146,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40146,1,3,0)
 ;;=3^Acute monoblastic/monocytic leukemia, in relapse
 ;;^UTILITY(U,$J,358.3,40146,1,4,0)
 ;;=4^C93.02
 ;;^UTILITY(U,$J,358.3,40146,2)
 ;;=^5001821
 ;;^UTILITY(U,$J,358.3,40147,0)
 ;;=C93.11^^156^1952^21
 ;;^UTILITY(U,$J,358.3,40147,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40147,1,3,0)
 ;;=3^Chronic myelomonocytic leukemia, in remission
 ;;^UTILITY(U,$J,358.3,40147,1,4,0)
 ;;=4^C93.11
 ;;^UTILITY(U,$J,358.3,40147,2)
 ;;=^5001823
 ;;^UTILITY(U,$J,358.3,40148,0)
 ;;=C93.12^^156^1952^20
 ;;^UTILITY(U,$J,358.3,40148,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40148,1,3,0)
 ;;=3^Chronic myelomonocytic leukemia, in relapse
 ;;^UTILITY(U,$J,358.3,40148,1,4,0)
 ;;=4^C93.12
 ;;^UTILITY(U,$J,358.3,40148,2)
 ;;=^5001824
 ;;^UTILITY(U,$J,358.3,40149,0)
 ;;=C93.91^^156^1952^38
 ;;^UTILITY(U,$J,358.3,40149,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40149,1,3,0)
 ;;=3^Monocytic leukemia, unspecified in remission
 ;;^UTILITY(U,$J,358.3,40149,1,4,0)
 ;;=4^C93.91
 ;;^UTILITY(U,$J,358.3,40149,2)
 ;;=^5001829
 ;;^UTILITY(U,$J,358.3,40150,0)
 ;;=C93.92^^156^1952^37
 ;;^UTILITY(U,$J,358.3,40150,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40150,1,3,0)
 ;;=3^Monocytic leukemia, unspecified in relapse
 ;;^UTILITY(U,$J,358.3,40150,1,4,0)
 ;;=4^C93.92
 ;;^UTILITY(U,$J,358.3,40150,2)
 ;;=^5001830
 ;;^UTILITY(U,$J,358.3,40151,0)
 ;;=E88.3^^156^1952^51
 ;;^UTILITY(U,$J,358.3,40151,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40151,1,3,0)
 ;;=3^Tumor lysis syndrome
 ;;^UTILITY(U,$J,358.3,40151,1,4,0)
 ;;=4^E88.3
 ;;^UTILITY(U,$J,358.3,40151,2)
 ;;=^338229
 ;;^UTILITY(U,$J,358.3,40152,0)
 ;;=C62.11^^156^1953^2
